Shireen Vali

2.6k total citations
67 papers, 2.1k citations indexed

About

Shireen Vali is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Shireen Vali has authored 67 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 20 papers in Hematology and 17 papers in Oncology. Recurrent topics in Shireen Vali's work include Cancer Genomics and Diagnostics (12 papers), Protein Degradation and Inhibitors (12 papers) and Multiple Myeloma Research and Treatments (10 papers). Shireen Vali is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), Protein Degradation and Inhibitors (12 papers) and Multiple Myeloma Research and Treatments (10 papers). Shireen Vali collaborates with scholars based in United States, Singapore and India. Shireen Vali's co-authors include Taher Abbasi, Shweta Kapoor, Gautam Sethi, Muthu K. Shanmugam, Alan Prem Kumar, Peramaiyan Rajendran, Kwang Seok Ahn, M. M. Srinivas Bharath, Rajeswara Babu Mythri and Ansu Kumar and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Shireen Vali

64 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shireen Vali United States	23	1.2k	497	294	198	189	67	2.1k
Numsen Hail United States	29	1.6k 1.4×	385 0.8×	326 1.1×	119 0.6×	148 0.8×	41	2.4k
Chulwon Kim South Korea	31	1.6k 1.3×	749 1.5×	469 1.6×	246 1.2×	359 1.9×	53	2.6k
Alessia Garufi Italy	20	1.3k 1.1×	593 1.2×	434 1.5×	86 0.4×	171 0.9×	38	2.2k
Sung‐Gook Cho South Korea	27	1.3k 1.1×	403 0.8×	315 1.1×	235 1.2×	175 0.9×	60	2.2k
Ravi P. Sahu United States	25	1.2k 1.0×	416 0.8×	285 1.0×	101 0.5×	117 0.6×	89	2.2k
A.R.M. Ruhul Amin United States	28	1.6k 1.4×	608 1.2×	475 1.6×	103 0.5×	308 1.6×	62	3.0k
Xiaohua Gao United States	29	1.7k 1.4×	223 0.4×	307 1.0×	254 1.3×	189 1.0×	94	3.1k
Ji Hoon Jung South Korea	31	1.5k 1.3×	472 0.9×	464 1.6×	89 0.4×	148 0.8×	116	2.6k
Tao Li China	30	1.3k 1.1×	315 0.6×	427 1.5×	66 0.3×	139 0.7×	149	2.4k
James O’Kelly United States	30	1.4k 1.2×	477 1.0×	243 0.8×	114 0.6×	492 2.6×	59	3.0k

Countries citing papers authored by Shireen Vali

Since Specialization

Citations

This map shows the geographic impact of Shireen Vali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shireen Vali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shireen Vali more than expected).

Fields of papers citing papers by Shireen Vali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shireen Vali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shireen Vali. The network helps show where Shireen Vali may publish in the future.

Co-authorship network of co-authors of Shireen Vali

This figure shows the co-authorship network connecting the top 25 collaborators of Shireen Vali. A scholar is included among the top collaborators of Shireen Vali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shireen Vali. Shireen Vali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aredo, Jacqueline V., Heather A. Wakelee, Kavitha Ramchandran, et al.. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports. 5(12). 100741–100741. 1 indexed citations

Loo, Ser Yue, Nicholas Syn, Amudha Deivasigamani, et al.. (2021). Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discovery. 7(1). 265–265. 12 indexed citations

Chong, Stephen Jun Fei, Jianhua Qu, Jayshree L. Hirpara, et al.. (2019). A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression. Cancer Letters. 457. 151–167. 22 indexed citations

Drusbosky, Leylah, Kimberly E. Hawkins, Glenda G. Anderson, et al.. (2018). iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).. Journal of Clinical Oncology. 36(15_suppl). 7024–7024.

Brogden, Kim A., Deepak Parashar, Terry A. Braun, et al.. (2018). Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer. 18(1). 225–225. 21 indexed citations

Tyner, Jeffrey, Brian Druker, Stephen E. Kurtz, et al.. (2018). Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study. Blood. 132(Supplement 1). 1540–1540. 1 indexed citations

Bates, Amber M., Carol L. Fischer, Deepak Parashar, et al.. (2016). Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunology Immunotherapy. 65(12). 1511–1522. 17 indexed citations

Kobayashi, Susumu, Shireen Vali, Ansu Kumar, et al.. (2016). Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget. 7(24). 35989–36001. 7 indexed citations

Jiang, Pengfei, Ying S. Chao, Ila Sri Bharati, et al.. (2014). Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Journal of Translational Medicine. 12(1). 13–13. 92 indexed citations

10.

Doudican, Nicole, Amitabha Mazumder, Shweta Kapoor, et al.. (2014). Predictive Simulation Approach for Designing Cancer Therapeutic Regimens with Novel Biological Mechanisms. Journal of Cancer. 5(6). 406–416. 9 indexed citations

11.

Pingle, Sandeep C., Sandra Pastorino, Pengfei Jiang, et al.. (2014). In silico modeling predicts drug sensitivity of patient-derived cancer cells. Journal of Translational Medicine. 12(1). 128–128. 25 indexed citations

12.

Brogden, Kim A., Georgia K. Johnson, Steven D. Vincent, Taher Abbasi, & Shireen Vali. (2013). Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses. Expert Review of Anti-infective Therapy. 11(10). 1097–1113. 20 indexed citations

13.

Kohlgraf, Karl G., et al.. (2013). Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus. Scientific Reports. 3(1). 1232–1232. 22 indexed citations

14.

Ramachandran, Lalitha, Kanjoormana Aryan Manu, Muthu K. Shanmugam, et al.. (2012). Isorhamnetin Inhibits Proliferation and Invasion and Induces Apoptosis through the Modulation of Peroxisome Proliferator-activated Receptor γ Activation Pathway in Gastric Cancer. Journal of Biological Chemistry. 287(45). 38028–38040. 126 indexed citations

15.

Manu, Kanjoormana Aryan, Muthu K. Shanmugam, Peramaiyan Rajendran, et al.. (2011). Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Molecular Cancer. 10(1). 107–107. 102 indexed citations

16.

Cirstea, Diana, Teru Hideshima, Scott J. Rodig, et al.. (2010). Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma. Molecular Cancer Therapeutics. 9(4). 963–975. 136 indexed citations

17.

Barve, Aditya, Anvita Gupta, Ansu Kumar, et al.. (2010). A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. PubMed. 3. 97–97. 10 indexed citations

18.

Equils, Ozlem, et al.. (2010). A Computer Simulation of Progesterone and Cox2 Inhibitor Treatment for Preterm Labor. PLoS ONE. 5(1). e8502–e8502. 15 indexed citations

19.

Roy, Karnati R., et al.. (2009). Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemotherapy and Pharmacology. 65(5). 903–911. 52 indexed citations

20.

Vali, Shireen, Shankar J. Chinta, Jie Peng, et al.. (2008). Insights into the effects of α-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. Free Radical Biology and Medicine. 45(9). 1290–1301. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact